Adverse Effects of Anti‐Covid‐19 Drug Candidates and Alcohol on Cellular Stress Responses of Hepatocytes
Atousa Khalatbari, Zahra Aghazadeh, Cheng Ji – 14 December 2021 – During the pandemic, dexamethasone (DEX), remdesivir (RDV), hydroxychloroquine (HCQ), thapsigargin (TG), camostat mesylate (CaM), and pralatrexate were repurposed drugs for coronavirus disease 2019 (COVID‐19). However, the side effects on the liver associated with the anti‐COVID therapies are unknown. Cellular stresses by these drugs at 0‐30 μM were studied using HepG2, Huh7, and/or primary human hepatocytes.
The Value of Liver and Spleen Stiffness for Evaluation of Portal Hypertension in Compensated Cirrhosis
Thomas Reiberger – 13 December 2021 – Patients with compensated advanced chronic liver disease who develop clinically significant portal hypertension (CSPH) are at high risk for hepatic decompensation and mortality if left untreated. Liver biopsy and hepatic venous pressure gradient (HVPG) measurements are the current gold standard procedures for determining fibrosis severity and diagnosing CSPH, respectively; however, both are invasive, limiting their use in clinical practice and larger trials of novel agents.
Letter to the editor: Autoimmune hepatitis after COVID‐19 vaccination: Need for population‐based epidemiological study
Yuji Suzuki, Keisuke Kakisaka, Yasuhiro Takikawa – 12 December 2021
Novel low‐avidity glypican‐3 specific CARTs resist exhaustion and mediate durable antitumor effects against HCC
Leidy D. Caraballo Galva, Xiaotao Jiang, Mohamed S. Hussein, Huajun Zhang, Rui Mao, Pierce Brody, Yibing Peng, Aiwu Ruth He, Mercy Kehinde‐Ige, Ramses Sadek, Xiangguo Qiu, Huidong Shi, Yukai He – 11 December 2021
Aiming for Functional Cure With Established and Novel Therapies for Chronic Hepatitis B
Hannah S.J. Choi, Alexander Tonthat, Harry L.A. Janssen, Norah A. Terrault – 9 December 2021 – Chronic hepatitis B virus (HBV) infection remains difficult to cure due to the persistent, self‐replenishing nature of the viral genome and impaired host immune responses. Current treatment goals for chronic hepatitis B (CHB) are to prevent or significantly delay liver‐related adverse outcomes and death, and two types of treatments are available: nucleos(t)ide analogues (NAs) and interferons (IFNs).
Fat‐associated lymphoid clusters as expandable niches for ectopic liver development
Bing Han, Maria Giovanna Francipane, Amin Cheikhi, Joycelyn Johnson, Fei Chen, Ruoyu Chen, Eric Lagasse – 9 December 2021
Reply
Jessica Musto, Michael R. Lucey, John Rice – 9 December 2021
NASHFit: A randomized controlled trial of an exercise training program to reduce clotting risk in patients with NASH
Jonathan G. Stine, Ian R. Schreibman, Alison J. Faust, Jessica Dahmus, Benjamin Stern, Christopher Soriano, Gloriany Rivas, Breianna Hummer, Scot R. Kimball, Nate R. Geyer, Vernon M. Chinchilli, Rohit Loomba, Kathryn Schmitz, Christopher Sciamanna – 9 December 2021
MutT Homolog 1 Inhibitor Karonudib Attenuates Autoimmune Hepatitis by Inhibiting DNA Repair in Activated T Cells
Yong Chen, Xiangwei Hua, Bingyuan Huang, Stella Karsten, Zhengrui You, Bo Li, You Li, Yikang Li, Jubo Liang, Jun Zhang, Yiran Wei, Ruiling Chen, Zhuwan Lyu, Xiao Xiao, Min Lian, Jue Wei, Jingyuan Fang, Qi Miao, Qixia Wang, Ulrika Warpman Berglung, Ruqi Tang, Thomas Helleday, Xiong Ma – 9 December 2021 – Autoimmune hepatitis (AIH) is an inflammatory liver disease driven by the hyperactivation of various intrahepatic antigen‐specific T cells due to a breach of immune tolerance.